ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ 4 THUỐC CÓ BISMUTH TIỆT TRỪ HELICOBACTER PYLORI Ở BỆNH NHÂN VIÊM LOÉT DẠ DÀY - TÁ TRÀNG TẠI BỆNH VIỆN 19/8 BỘ CÔNG AN

Abstract

Objective: To evaluate the treatment effectiveness of the 4-drug regimen with Bismuth (EBMT) in the treatment of gastric and duodenal ulcers caused by Helicobacter pylori (HP) infection at August 19 Hospital - Ministry of Public Security, period 2021 - 2023. Methods: A cross-sectional descriptive study on 334 patients examined at the Internal Medicine Gastroenterology clinic, 19/8 hospital, Ministry of Public Security from January 2021 to June 2023. The patient was diagnosed with gastric and duodenal ulcers and was diagnosed with Helicobacter pylori infection. All patients were treated with a 4-drug regimen containing Bismuth including: Esomeprazole 40mg 2 times/day, Bismuth 120mg 4 times/day, Metronidazole 250mg 4 times/day and Tetracycline 500mg 4 times/day for 14 days, with only Esomeprazole taken orally for a long time. for an additional 2 weeks with a dose of 40mg/day. Within 4-8 weeks after the end of treatment, the patient is scheduled for a follow-up examination to evaluate the effectiveness of HP eradication. The remaining HP infection status is checked again with Chlorine test or Urease breath test. Results: The HP eradication success rate was 94.9%, the failure rate was 5,1%. The rateof successful eradication of HP in groups under 40 years old, 40-59 years old and ≥ 60 years old were 97,3%, 94,3% and 76.7%, respectively. The difference in HP eradication rate in these three groups was statistically significant (p=0.004). Side effects occurred in 15,6%. The common side effects were nausea, headache and diarrhea. Conclusion: Bismuth-containing quadruple regimen achieved very high eradication rates. Side effects were uncommon but not sever.